Last reviewed · How we verify
Dapsone 5.0% Gel (SEEGPharm)
Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production.
Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production. Used for Acne vulgaris (topical gel formulation), Rosacea (potential indication based on anti-inflammatory properties).
At a glance
| Generic name | Dapsone 5.0% Gel (SEEGPharm) |
|---|---|
| Also known as | Experimental Arm |
| Sponsor | Seegpharm S.A. |
| Drug class | Sulfone antibiotic with anti-inflammatory properties |
| Target | Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Dapsone works through dual mechanisms: as an antimicrobial agent targeting bacterial folate synthesis, and as an immunomodulator that reduces neutrophil-mediated inflammation. In topical gel formulation, it penetrates skin to suppress inflammatory pathways relevant to acne and other dermatological conditions. The anti-inflammatory effects are particularly useful in conditions driven by neutrophil activation and oxidative stress.
Approved indications
- Acne vulgaris (topical gel formulation)
- Rosacea (potential indication based on anti-inflammatory properties)
Common side effects
- Local skin irritation
- Erythema
- Dryness
- Contact dermatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapsone 5.0% Gel (SEEGPharm) CI brief — competitive landscape report
- Dapsone 5.0% Gel (SEEGPharm) updates RSS · CI watch RSS
- Seegpharm S.A. portfolio CI